RecruitingNot Applicable

Biomarker Signature-Supported Antibiotic Treatment Decisions in ICU

Canada1,200 participantsStarted 2025-05-13

Plain-language summary

The goal of this randomized clinical trial is to determine whether a biomarker-signature (BV) supported antibiotic treatment decision matrix can have a beneficial impact on antibiotic use and patient outcomes in an ICU population.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Congenital immunodeficiency
✕. HIV with CD4 \< 20
✕. Active chemotherapy and profound neutropenia (ANC \< 100) expected to last \> 7 days;
✕. solid organ or stem cell transplant within preceding 6 months AND active GVHD
✕. Receiving high dose steroids (Pred \> 20mg/day for \> or = 2 weeks)

What they're measuring

Desirability of Outcome Ranking Adjusted for Antibiotic Risk (DOOR-RADAR)

Timeframe: 28 days+/- 2

Trial details

NCT IDNCT07481773

SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-05

Contact for this trial

Makeda Semret, MD

15149341934 makeda.semret@mcgill.ca

View on ClinicalTrials.gov More Intensive Care Unit (ICU) Admission trials